Anticancer drug development [electronic resource] / edited by Bruce C. Baguley, David J. Kerr.Material type: TextPublisher: San Diego : Academic Press, c2002Description: 1 online resource (xiii, 397 p.) : ill. (some col.)ISBN: 9780120726516; 0120726513; 9780080490441 (electronic bk.); 0080490441 (electronic bk.)Subject(s): Antineoplastic agents | Drug development | Antineoplastic Agents | Drug Design | Drug Evaluation, Preclinical | Anticanc�ereux -- D�eveloppement | Cancer -- Chimioth�erapie | MEDICAL -- Oncology | HEALTH & FITNESS -- Diseases -- CancerGenre/Form: Electronic books.Additional physical formats: Print version:: Anticancer drug development.DDC classification: 616.99/4061 LOC classification: RS431.A64 | A564 2002ebOnline resources: ScienceDirect
Here in a single source is a complete spectrum of ideas on the development of new anticancer drugs. Containing concise reviews of multidisciplinary fields of research, this book offers a wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death. Detailed descriptions of sources for new drugs and methods for testing and clinical trial design are also provided. KEY FEATURES: * One work that can be consulted for all aspects of anticancer drug development * Concise reviews of research fields, combined with practical scientific detail, written by internationally respected experts * A wealth of ideas on current and future molecular targets for drug design, including signal transduction, the cell division cycle, and programmed cell death * Detailed descriptions of the sources of new anticancer drugs, including combinatorial chemistry, phage display, and natural products * Discussion of how new drugs can be tested in preclinical systems, including the latest technology of robotic assay systems, cell culture, and experimental animal techniques * Hundreds of references that allow the reader to access relevant scientific and medical literature * Clear illustrations, some in color, that provide both understanding of the field and material for teaching.
Includes bibliographical references and index.
A brief history of cancer chemotherapy -- Novel targets in the cell cycle and cell cycle checkpoints -- Growth factor and signal transduction targets for cancer therapy -- Cell death pathways as targets for anticancer drugs -- Drug resistance pathways as targets -- Role of matrix metalloproteinases and plasminogen activators in cancer invasion and metastasis: therapeutic strategies -- Tumor vasculature as a target -- Gene-directed enzyme prodrug therapy -- Tumor antigens as targets for anticancer drug development -- Structure-based drug design and its contributions to cancer chemotherapy -- The contribution of synthetic organic chemistry to anticancer drug development -- Biosynthetic products for anticancer drug design and treatment: the bryostatins -- DNA-encoded peptide libraries and drug discovery -- Mechanism-based high-throughput screening for novel anticancer drug discovery -- Tumor cell cultures in drug development -- Screening using animal systems -- Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques: relevance of animal toxicity -- Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic, and pharmacogenetic principle -- Tumor imaging applications in the testing of new drugs -- Mechanistic approaches to Phase I clinical trials.
Description based on print version record.